MedTrace Logo

Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic

NCT03542786 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2020-07-08

No results posted yet for this study

Summary

The main purpose of this study is to evaluate a therapy for the inflammaging (premature aging).

Conditions

  • HIV
  • Premature Aging

Interventions

DIETARY_SUPPLEMENT

Probiotic

The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A. It contains: * Lactobacillus plantarum CECT7484 * Lactobacillus plantarum CECT7485 * Pediococcus acidilactici CECT7483

DIETARY_SUPPLEMENT

Prebiotic

ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A. It contains: * Partially Hydrolyzed Guar Gum (PHGG) * Inulin HPD * Oat Beta-Glucans * Pectin * Inulin Low Protein Diet (LPD) * Polydextrose * Maltrodextrins

DIETARY_SUPPLEMENT

Placebo

It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.

Sponsors & Collaborators

  • Germans Trias i Pujol Hospital

    collaborator OTHER

  • AB Biotics, SA

    lead INDUSTRY

Principal Investigators

  • Ariana Salavert, PhD · AB-Biotics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-18
Primary Completion
2020-02-29
Completion
2020-02-29

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542786 on ClinicalTrials.gov